ライフサイエンスコーパス: HIV antibody

1 mutants has not been delineated for an anti-HIV antibody.

2 llomavirus (HPV), Neisseria gonorrhoeae, and HIV antibody.

3 nd intravenous immunoglobulin (IVIG) without HIV antibody.

4 um samples that were repeatedly reactive for HIV antibodies.

5 n more potent than broadly neutralizing anti-HIV antibodies.

6 ty than well-known broadly neutralizing anti-HIV antibodies.

7 mens that had previously tested positive for HIV antibodies.

8 e enterotoxin (shortest distance 31 A), anti-HIV antibody 2G12 (shortest distance 31 A), concanavalin

9 recognized by the broadly neutralizing anti-HIV antibody 2G12 are 3-fold more abundant on the native

10 hich were recognized by broadly neutralizing HIV antibody 2G12 with moderate affinities (150-500 nM K

11 proteins (Aspergillus niger phytase and anti-HIV antibody 2G12) produced in different plant species a

12 The broadly neutralizing anti-HIV antibody 4E10 recognizes an epitope very close to th

13 s) claim to detect both p24 antigen (Ag) and HIV antibodies (Ab) for early identification of acute in

14 An HIV antibody (Ab) against platelet integrin GPIIIa49-66

15 esting and blood screening algorithms detect HIV antibodies about 3 weeks after HIV infection.

16 he presence of maternal or administered anti-HIV antibody, alternative strategies may be required to

17 after the exposure, no participant developed HIV antibodies, although a second PEP course for a subse

18 o determine the frequency of vaccine-induced HIV antibody among uninfected HIV vaccine trial particip

19 These distinctive activities suggest that HIV antibodies and their derivatives may play an importa

20 was to determine the timing of clearance of HIV antibodies and to identify any associated biological

21 Screening for HIV antibodies and viral RNA every 6 months has an ICER

22 yearly follow-up visits included testing for HIV antibody and assessment of behavioural outcomes.

23 ot with HIV(IIIB), allowing for detection of HIV antibodies approximately 3 weeks earlier than by RT-

24 Broadly neutralizing HIV antibodies are much sought after (a) to guide vaccin

25 Broadly neutralizing anti-HIV antibodies are rare and have proved hard to elicit w

26 Anti-HIV antibodies are therefore of great interest for vacci

27 Human immunodeficiency virus (HIV) antibodies are generated and maintained by ongoing

28 Sensitivity and specificity of a rapid HIV antibody assay based on comparisons with nonrapid as

29 s of relatively inexpensive and quantitative HIV antibody assays may be useful indirect markers that

30 en percent of the infants had persistence of HIV antibodies at or beyond 18 months of age.

31 se the recognition of infected cells by anti-HIV antibodies at the cell surface, thereby reducing rec

32 tive for hepatitis B surface antigen or anti-HIV antibody at screening, or if they had previously bee

33 In conclusion, HIV antibody avidity testing provides a reliable method

34 vectors encoding a secretory monoclonal anti-HIV antibody, b12 (IgG(1)), we were able to program huma

35 in the United States and tested positive for HIV antibodies between 1988 and 1997 while living in the

36 Broadly neutralizing HIV antibodies (bNAbs) can recognize carbohydrate-depend

37 Apex broadly neutralizing HIV antibodies (bnAbs) recognize glycans and protein sur

38 t a targeted conjugate consisting of an anti-HIV antibody bound to a toxic moiety could function to k

39 In all, 4311 men were tested for HIV antibodies by enzyme-linked immunosorbent assay, wit

40 Passive transfer of broadly neutralizing HIV antibodies can prevent infection, which suggests tha

41 mbinations of polyclonal and monoclonal anti-HIV antibodies can produce additive or synergistic neutr

42 es aimed at stabilizing this region in other HIV antibodies could become an important approach to in

43 , (iii) potentiates the non-membrane-binding HIV antibody D5 10-100-fold (depending on the virus stra

44 For visual or electronic reader HIV antibody detection, the sensitivity was 100% and the

45 mmunoassay for human immunodeficiency virus (HIV) antibody detection that localizes capture and detec

46 Higher levels of HIV antibodies during suppressive therapy were associate

47 Thus, comprehensively mapping HIV antibody escape gives a quantitative, mutation-level

48 Screening for HIV antibodies every 6 months costs $30,700/QALY gained.

49 eveloped to exploit the titer and avidity of HIV antibody evolution following seroconversion for inci

50 s encoding a mixture of broadly neutralizing HIV antibodies for the treatment of HIV infection, parti

51 mined for subjects who remained negative for HIV antibody for >or=3 months.

52 roup of related molecules, we cloned 576 new HIV antibodies from four unrelated individuals.

53 ogen design and as a bait for isolating anti-HIV antibodies from patient samples.

54 We have cloned anti-HIV antibodies from the memory B-cell compartment of six

55 A series of potent, broadly neutralizing HIV antibodies have been isolated from B cells of HIV-in

56 Recently, several neutralizing anti-HIV antibodies have been isolated from memory B cells of

57 Eligible data on prevalence of IDU, HIV antibody, HBsAg, and HCV antibody among PWID were se

58 Clinical information and levels of HIV antibody, HIV RNA, and p24 antigen.

59 Both assays detected HIV antibodies in men and women within 2 to 4 weeks of i

60 Clearance of HIV antibodies in uninfected infants was found to occur

61 we show that the polymeric IgA form of anti-HIV antibody inhibits HIV mucosal transmission more effe

62 Combining the detection of syphilis and HIV antibodies into one point-of-care test integrates sy

63 studies, the time to seroconversion for anti-HIV antibodies is 1-9 months (mean, approximately 2-3 mo

64 nistration-approved enzyme immunoassay (EIA) HIV antibody kits were used to determine VISP, and a rou

65 Fourteen people with acute HIV infection (HIV antibody negative/NAT positive) were identified; the

66 3.3% of 1,656 treatment-naive, HIV antibody-negative individuals ultimately achieved SV

67 Of 3874 HIV antibody-negative persons tested, 58 (1.5%) were p24

68 inics in India, screening for p24 antigen in HIV antibody-negative persons was found to be a reliable

69 V Combo] assay; Abbott Diagnostics) in 2,744 HIV antibody-negative samples.

70 NAAT identified 13 (0.1%) of the 12,338 HIV antibody-negative specimens as HIV RNA positive, wit

71 to HIV-infected mothers, 299 children became HIV-antibody-negative and 264 of these had been followed

72 gp160 enzyme immunoassay (EIA), detection of HIV antibodies occurred, on average, 33 days earlier tha

73 ASI reported having sexual partners who were HIV antibody positive (odds ratio = 1.36, 95% confidence

74 d those who knew that the source subject was HIV antibody positive were more likely to recruit their

75 607/694 (87%) participants tested were HIV antibody positive.

76 Comprehensive HIV antibody profiles may prove useful for monitoring cu

77 HIV rapid tests (RTs) for anti-HIV antibodies provide results in less than 1 h and can

78 mune response to HIV often occurs-serum anti-HIV antibodies reactive with live HIV-infected cells, te

79 n induced a distinct and characteristic anti-HIV antibody response that, in some animals, included ne

80 d the extent of participation in the initial HIV antibody response, if any, are unclear.

81 We investigated whether HIV antibody responses as measured by high-throughput qu

82 vaccine might consider eliciting protective HIV antibody responses selectively from alternative B-ce

83 HIV antibody responses were measured over time in the pr

84 rategies to enhance systemic and mucosal SIV/HIV antibody responses.

85 We compared HIV antibody results between two of three treatment grou

86 e U.S. Food and Drug Administration-licensed HIV antibody screening, p24 antigen tests, HIV confirmat

87 t on a nucleic acid amplification test or as HIV antibody seroconversion.

88 ns with recent human immunodeficiency virus (HIV) antibody seroconversion is useful for treatment, re

89 pendently associated with p24 antigenemia in HIV antibody-seronegative persons included fever, which

90 found to encode broadly neutralizing mutated HIV antibodies, such as VRC01.

91 rithm) as well as 1 algorithm that relies on HIV antibody testing alone (Antibody algorithm).

92 spective living organ donors, and to conduct HIV antibody testing and NAT as close to the time of don

93 us self-administered questionnaires and oral HIV antibody testing in MSM recruited in gay social venu

94 Physicians must perform HIV antibody testing to determine which persons are alre

95 Assessments included rapid HIV antibody testing, VL, and CD4+ T-cell count via fing

96 Peripheral blood samples were obtained for HIV antibody testing.

97 approximately 10% compared with conventional HIV antibody testing.

98 pared the diagnostic performance of standard HIV antibody tests (i.e., enzyme immunoassay and Western

99 HIV antibody tests cannot be used to reconfirm HIV diagn

100 man immunodeficiency virus (HIV) to standard HIV antibody tests to detect persons with acute HIV infe

101 Rapid human immunodeficiency virus (HIV) antibody tests support the effort to expand access

102 Thus far, however, few broadly neutralizing HIV antibodies that occur naturally have been characteri

103 A fourth panel possessed early HIV antibodies that reacted with HIV(213) but not with H

104 with live HIV-infected cells, termed "early HIV antibodies." The specificities of these antibodies a

105 , however, are the unique properties of anti-HIV antibodies: the potential ability to opsonize viral

106 Anti-HIV antibody titers did not differ between study arms.

107 nability of most known specificities of anti-HIV antibodies to neutralise HIV primary isolates consis

108 ministered a macaque version of a human anti-HIV antibody to monkeys, after which the antibody persis

109 The detection of HIV antibodies was achieved with an electrochemical immu

110 tion, the addition of one-time screening for HIV antibodies with an enzyme-linked immunosorbent assay